Loading…
Terumo Corporation has secured exclusive global development and commercialization rights to the Virtue Sirolimus-Eluting Balloon by entering into a strategic partnership with Orchestra BioMed. Terumo will make a $30 million upfront payment and a $5 million equity commitment.
“Terumo today announced that it has secured exclusive global development and commercialization rights to Virtue Sirolimus-Eluting Balloon for percutaneous coronary interventions.”terumois.com
Summarized from public sources; check the original articles before acting on it.